Arsani  William net worth and biography

Arsani William Biography and Net Worth

Director of Design Therapeutics
Arsani William, M.D. has served as a member of our board of directors since January 2021. Dr. William has served as Managing Partner and Chief Investment Officer of Logos Capital since its founding in 2019. Prior to founding Logos, Dr. Williams served as an investment professional at Farallon Capital Management. Dr. Williams holds an M.D. from Harvard Medical School where he was a Gerald S. Foster Scholar, an MBA from Stanford’s Graduate School of Business, and a BS with Honors in Biology from Stanford University.

How do I contact Arsani William?

The corporate mailing address for Dr. William and other Design Therapeutics executives is 6005 HIDDEN VALLEY ROAD SUITE 110, CARLSBAD CA, 92011. Design Therapeutics can also be reached via phone at 858-293-4900 and via email at [email protected]. Learn More on Arsani William's contact information.

Has Arsani William been buying or selling shares of Design Therapeutics?

Arsani William has not been actively trading shares of Design Therapeutics during the last ninety days. Most recently, Arsani William sold 814,874 shares of the business's stock in a transaction on Friday, August 9th. The shares were sold at an average price of $4.25, for a transaction totalling $3,463,214.50. Learn More on Arsani William's trading history.

Are insiders buying or selling shares of Design Therapeutics?

In the last year, Design Therapeutics insiders bought shares 2 times. They purchased a total of 26,965 shares worth more than $99,750.38. In the last year, insiders at the sold shares 1 times. They sold a total of 814,874 shares worth more than $3,463,214.50. The most recent insider tranaction occured on August, 9th when Director Arsani William sold 814,874 shares worth more than $3,463,214.50. Insiders at Design Therapeutics own 31.2% of the company. Learn More about insider trades at Design Therapeutics.

Information on this page was last updated on 8/9/2024.

Arsani William Insider Trading History at Design Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/9/2024Sell814,874$4.25$3,463,214.50View SEC Filing Icon  
3/21/2022Buy25,000$18.99$474,750.00View SEC Filing Icon  
8/31/2021Buy40,000$15.45$618,000.00View SEC Filing Icon  
See Full Table

Arsani William Buying and Selling Activity at Design Therapeutics

This chart shows Arsani William's buying and selling at Design Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Design Therapeutics Company Overview

Design Therapeutics logo
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $5.80
Low: $5.61
High: $5.98

50 Day Range

MA: $5.51
Low: $4.56
High: $7.50

2 Week Range

Now: $5.80
Low: $2.13
High: $7.77

Volume

240,519 shs

Average Volume

135,472 shs

Market Capitalization

$328.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83